Ludwig Institute for Cancer Research
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Ludwig Institute for Cancer Research sits in the top decile of US sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count).
Ludwig Institute for Cancer Research: 30 sponsored US clinical trials, none currently recruiting.
Ludwig Institute for Cancer Research sponsors 30 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 24 completed. 0 of these trials are in Phase 3-4 (later-stage) and 30 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peritoneal Cavity Cancer, with 1 trials.
Top-decile sponsor footprint
Ludwig Institute for Cancer Research ranks in the top decile of sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
24 of 30 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
30 total, page 1 of 1
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
NCT03164772
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
NCT02963831
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
NCT02898116
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
NCT02643303
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
NCT02716805
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
NCT02659540
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
NCT02431559
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
NCT02336165
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
NCT01810016
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
NCT01975831
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
NCT01380145
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
NCT01266018
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
NCT00803569
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
NCT00679289
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00616941
Study of ADI-PEG 20 in Patients With Advanced Melanoma
NCT00520299
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
NCT00299728
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
NCT00142454
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
NCT00199875
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
NCT00140855
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
NCT00199888
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00112957
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
NCT00199849
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
NCT00084799
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
NCT00072410
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
NCT00070070
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00066729
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
NCT00006099
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
NCT00006046
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
NCT00003102
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 5 |
Therapeutic Areas
How the Ludwig Institute for Cancer Research early-phase archive is shaped
30 indexed studies, none listed as recruiting (0% open); 24 completed (80%).
Phase mix: 0 late (III/IV) vs 30 early (I/II) (early-phase heavy).
Top condition: Peritoneal Cavity Cancer (1 trial), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Ludwig Institute for Cancer Research: archived-pipeline peers nationwide
Peers matched on 30 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Ludwig Institute for Cancer Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 30 archived trials
- Biotronik · 30 trials · 3% recruiting
- Charles Drew University of Medicine and Science · 30 trials · 3% recruiting
- Chiesi Farmaceutici S.p.A. · 30 trials · 13% recruiting
- Debiopharm International · 30 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Ludwig Institute for Cancer Research page
30 registered trials is a research-attention snapshot, not an endorsement of Ludwig Institute for Cancer Research or any single study.
- None of Ludwig Institute for Cancer Research's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Peritoneal Cavity Cancer is the condition Ludwig Institute for Cancer Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peritoneal Cavity Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ludwig Institute for Cancer Research pipeline card: 30 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.